Clostridioides difficile
From IDWiki
Clostridioides difficile
Microbiology
- Spore-forming, anaerobic, Gram-positive bacillus
Severity
| Severity | Definition |
|---|---|
| Mild | WBC ≤15 AND creatinine ≤1.5 x baseline |
| Severe, uncomplicated | WBC >15 OR creatinine >1.5 x baseline OR hypoalbuminemia |
| Severe, complicated | Hypotension OR shock OR ileus OR megacolon |
Management
Further Reading
- AMMI treatment practice guidelines for Clostridium difficile infection 2018
- Clostridioides difficile: diagnosis and treatments. BMJ. 2019;366:l4609. doi: 10.1136/bmj.l46091
References
- a b Kevin A. Brown, Nagham Khanafer, Nick Daneman, David N. Fisman. Meta-Analysis of Antibiotics and the Risk of Community-Associated Clostridium difficile Infection. Antimicrobial Agents and Chemotherapy. 2013;57(5):2326-2332. doi:10.1128/aac.02176-12.
- ^ Aaron C Miller, Alan T Arakkal, Daniel K Sewell, Alberto M Segre, Joseph Tholany, Philip M Polgreen. Comparison of Different Antibiotics and the Risk for Community-Associated Clostridioides difficile Infection: A Case–Control Study. Open Forum Infectious Diseases. 2023;10(8). doi:10.1093/ofid/ofad413.
- a b Mayan Gilboa, Gili Regev-Yochay, Eyal Meltzer, Ido Cohen, Yovel Peretz, Tal Zilberman-Daniels, Amitai Segev, Sharon Amit, Dafna Yahav, Noam Barda. Antibiotic Use and the Risk of Hospital-Onset Clostridioides Difficile Infection. JAMA Network Open. 2025;8(8):e2525252. doi:10.1001/jamanetworkopen.2025.25252.
- ^ Yangxi Liu, Mengfei Dai, Kanghuai Zhang, Li Zhang, Bin Lin, Keyu Chen, Haitao Wang, Zhichun Gu, Yuetian Yu, Yan Wang. Risk of Clostridioides difficile infection following different antibiotics: insights from multi-source medical data. International Journal of Antimicrobial Agents. 2024;64(4):107288. doi:10.1016/j.ijantimicag.2024.107288.
- a b Vivian G Loo, Ian Davis, John Embil, Gerald A Evans, Susy Hota, Christine Lee, Todd C Lee, Yves Longtin, Thomas Louie, Paul Moayyedi, Susan Poutanen, Andrew E Simor, Theodore Steiner, Nisha Thampi, Louis Valiquette. Association of Medical Microbiology and Infectious Disease Canada treatment practice guidelines for Clostridium difficile infection. Official Journal of the Association of Medical Microbiology and Infectious Disease Canada. 2018;3(2):71-92. doi:10.3138/jammi.2018.02.13.
- ^ Clostridium difficile Infection in Infants and Children. Pediatrics. 2012;131(1):196-200. doi:10.1542/peds.2012-2992.
- ^ Mazen S. Bader, John Hawboldt, Cheryl Main, Dominik Mertz, Mark Loeb, Alison Farrell, Joanna Joyce. Review of high dose vancomycin in the treatment of Clostridioides difficile infection. Infectious Diseases. 2020;52(12):847-857. doi:10.1080/23744235.2020.1800080.
- ^ Caio T Heleno, Aleksey Tagintsev, Katharine Lasley, Douglas Summerfield. Fidaxomicin as a Salvage Therapy for Fulminant Clostridioides difficile Infection. Cureus. 2021. doi:10.7759/cureus.16559.
- ^ Emma C. Phillips, Cirle A. Warren, Jennie Z. Ma, Gregory R. Madden. Impact of Tigecycline on C. difficile Outcomes: Case Series and Propensity-Matched Retrospective Study. Antimicrobial Agents and Chemotherapy. 2022;66(6). doi:10.1128/aac.00001-22.
- ^ Andrew M Skinner, Xing Tan, Benjamin D Sirbu, Larry H Danziger, Dale N Gerding, Stuart Johnson. A Tapered-pulsed Fidaxomicin Regimen Following Treatment in Patients With Multiple Clostridioides difficile Infection Recurrences. Clinical Infectious Diseases. 2021;73(6):1107-1109. doi:10.1093/cid/ciab233.
- ^ Hoonmo L. Koo, Diana C. Koo, Daniel M. Musher, Herbert L. DuPont. Antimotility Agents for the Treatment ofClostridium difficileDiarrhea and Colitis. Clinical Infectious Diseases. 2009;48(5):598-605. doi:10.1086/596711.
- ^ Steven W Johnson, Shannon V Brown, David H Priest. Effectiveness of Oral Vancomycin for Prevention of Healthcare Facility–Onset Clostridioides difficile Infection in Targeted Patients During Systemic Antibiotic Exposure. Clinical Infectious Diseases. 2019;71(5):1133-1139. doi:10.1093/cid/ciz966.
